Theralink Technologies Inc (THER)

[BooDog]

"PICK ME! PICK ME!!" $OBMP cries loudly.

“Looking ahead to 2019, it appears likely that the arms race of mega-deals into startups backed by a growing number of mega-funds will continue,” the report said.


Of course we need to see proper funding. And soon.


Would like to see them move forward on their PGT technology. There could be some real potential there.

BATON ROUGE, LA–(July 6, 2016) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders of results of pre-clinical research that support further development of the Company’s patented, novel paclitaxel gallium transferrin (PGT) technology for the treatment of multiple types of cancer.

OncBioMune first tested PGT against a series of human cell lines to evaluate activity in models of breast, colon, lung and three human cell lines of ovarian cancer, including a drug-resistant ovarian cancer model. The results showed PGT to act as an inhibitor of all tumor cell lines, including the drug-resistant ovarian cancer model.

OncBioMune then conducted research to develop an animal model to evaluate the activity of PGT and selected the 4T1 murine mammary carcinoma tumor model. The 4T1 murine mammary carcinoma is recognized as one of the most aggressive cancer cell lines and is known to rapidly metastasize to sites similar to human breast cancer. OncBioMune developed its own 4T1 mouse model and showed an intraperitoneal injection of PGT worked as an inhibitor of 4T1 mammary tumors. Importantly, no gross organ toxicities at necropsy were observed.

http://oncbiomune.com/2016/07/06/oncbiomune-research-shows-activity-of-pgt-technology-in-a-mammary-cancer-animal-model/